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INVESTIGATION OF THE ANTI-MIGRATORY PROPERTIES OF GSK-3 
INHIBITORS IN GLIOBLASTOMA 
HILLARY ROLFS 
ABSTRACT 	
 Glioblastoma is the most malignant form of brain cancer. Due to its aggressive 
nature, extensive research has been performed, but little progress has been made in 
identifying effective treatment options. Glycogen synthase kinase-3 (GSK-3) is a 
ubiquitous, multifaceted protein kinase. Previous studies have shown that small molecule 
inhibitors of GSK-3 block the migration of glioblastoma cells and may prevent spread of 
tumor in the brain. However, these studies were performed using non-selective GSK-3 
inhibitors (LiCl and an indirubin derivative, BIO), thus it was unclear whether GSK-3 
was the most important target. In this study, we used recently generated highly selective 
GSK-3 inhibitors (CHIR99021, AZD1080, and AZD2858, as well as BIO) to investigate 
these questions. These were applied to four glioblastoma cell lines: G30, G9, U251, and 
U1242, in three migration assays: transwell, spheroid, and wound healing (scratch) assay 
to further assess the suitability of GSK-3 as a target in glioblastoma. We also utilized the 
ATP Luciferase reporter assay for cell viability to assess the influence of our panel of 
drugs on cell migration versus viability. In addition, the TOPFlash Luciferase reporter 
assay was performed as an indicator of the level of GSK-3 inhibition.  
 The TOPFlash assay showed that all GSK-3 inhibitors were able to increase 
luciferase levels. This indicates that GSK-3 was inhibited in our cells after drug 
treatment. The transwell assays showed us that the GSK-3 inhibitors were able to block 
		 vii 
migration significantly in all cell lines tested in a dose-dependent manner. The 
effectiveness of GSK-3 inhibition in the three-dimensional collagen spheroid assays was 
cell line-dependent, with the non-selective GSK-3 inhibitor BIO showing the most potent 
effects. Cell migration was not blocked by any of the three selective GSK-3 inhibitors in 
the wound healing scratch assay. Thus we have found that the three distinct highly 
selective inhibitors of GSK-3 block glioblastoma cell migration, but only work 
consistently in the transwell assay. Therefore, we conclude that GSK-3 might be 
important in the contraction and morphological changes necessary for glioblastoma cells 
to migrate through the 8 micron pores in the transwell. Further investigation into this 
observation is necessary. Though results were variable between assays, we conclude that 
the inhibition of GSK-3 is a promising potential therapeutic strategy for glioblastoma 
treatment.  
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INTRODUCTION 
 
1. GLIOBLASTOMA: THE MOST COMMON AND THERAPEUTICAL 
CHALLENGING MALIGNANT BRAIN TUMOR 
Glioblastoma is the most aggressive malignant primary brain tumor; its 
destructive nature combined with minimal success in advancing treatment options has led 
to a prognosis of 14-16 months median survival, with approximately 5% of patients 
surviving more than 5 years past diagnosis (Knights, 2015; Neagu & Reardon, 2015). The 
tumor’s sensitive location, and the presence of infiltrating cells prevent complete surgical 
resection, and cause inevitable recurrence (Knights, 2015). Though glioblastoma cells are 
highly invasive, they typically do not metastasize outside of the central nervous system 
(Omuro A & DeAngelis LM, 2013). Glioblastoma is also highly resistant to treatment 
because of its heterogeneity, and the challenge of drug delivery across the blood brain 
barrier (BBB) (Knights, 2015).  
1.1 Epidemiology 	
Glioblastoma has an incidence of 2-3 cases per 100,000 people in Europe and North 
America. Though this may appear to be a low number, glioblastoma is the fourth greatest 
cause of cancer death (Weingart, McGirt, & Brem, 2010).  Glioblastoma is more 
common with increasing age, with the highest incidence in 75-84 year olds (Ostrom et 
al., 2014); however, cases are also reported in infants (Urbańska, Sokołowska, Szmidt, & 
Sysa, 2014). The ratio of cases in men as compared to women is 1.26:1 (Ostrom et al., 
2014).  
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Figure 1. Glioma 2-year survival by age and histologic subtype, based on individuals diagnosed between 1973 
and 2002. Seen here is the decreased survival rates of the elderly population with glioblastoma. Figure taken from 
(Schwartzbaum, Fisher, Aldape, & Wrensch, 2006).  
1.2 Potential Causes  
1.2.1 Rare Hereditary Syndromes 	
Around 5% of glioblastomas arise from hereditary syndromes (Malmer et al., 
2001). Ostrom et al. have recognized mutations in the tumor suppressor gene p53 in 
approximately 30% of gliomas (Ostrom et al., 2014). Li-Fraumeni Syndrome is a rare 
hereditary disorder commonly associated with germline mutations in p53, and is 
consequently a risk factor for glioblastoma (Omuro A & DeAngelis LM, 2013). In 
studies by Therkildsen et al., 14% of patients with Lynch Syndrome developed brain 
tumors, with 56% of these tumors being glioblastomas (Omuro A & DeAngelis LM, 
2013). Cowden syndrome, Turcot syndrome, Neurofibromatosis type 1 and 2, tuberous 
scleroris, melanoma-neural system tumor syndrome, and familial schwannomatosis are 
other hereditary diseases associated with glioblastoma development (Barani & Larson, 
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2015; Omuro A & DeAngelis LM, 2013). More recent additions to this list include Ollier 
disease/Maffuci syndrome (Barani & Larson, 2015).  
1.2.2 Susceptibility Variants from Genome-wide Studies 
  
The Cancer Genome Atlas (TCGA) has characterized approximately 500 patient 
glioblastoma tumor samples by comprehensive genomic and transcriptomic profiling. 
From this data they found no two tumors have the same mutations, i.e. glioblastoma is a 
heterogenous disease (Omuro A & DeAngelis LM, 2013). However, 7 genomic variants 
that increased glioma risk were identified: telomerase reverse transcriptase (TERT), 
epidermal growth factor receptor (EGFR), coiled-coil domain containing 26 (CCDC26), 
pleckstrin homology-like domain family B member 1 (PHLDB1), p53, and regulator of 
telomere elongation helicase (RTEL1) (Barani & Larson, 2015).  
1.2.3 Growth Factor Downstream Signaling  	
Growth factor downstream signaling also plays a large role in glioblastoma 
development; signaling pathways are altered in 88% of glioblastoma cases (Knights, 
2015). Amplification of the EGFR gene and overexpression of protein was indicated in 
40% of glioblastoma cases. This promotes cell proliferation via the Phosphoinositide 3-
kinase (PI3K)/Protein Kinase B (Akt) pathway, enhancing Shc and Grb2 coordination, 
and Ras activity, as well as promoting cell survival by increasing expression of Bcl-XL 
and other antiapoptotic proteins, and dysregulating cell cycle inhibitors such as 
p27KIP1(Knights, 2015). Mutations in EGFR also enhance angiogenesis and cell migration 
via vascular endothelial growth factor, interleukin-8, and matrix metalloproteinase 13 
(Knights, 2015). Also commonly mutated is the upstream inhibitor of PI3K, phosphatase 
	4 
and tensin homolog (PTEN), in addition to the neurofibromatosis 1 gene (NF1) (Barani & 
Larson, 2015).  
1.2.4 Ionizing Radiation 	
The sole firmly established environmental risk factor for developing glioblastoma 
is ionizing radiation (Knights, 2015). The propensity for persons exposed to ionizing 
radiation to develop glioblastoma is also correlated with a genetic predisposition for 
cancer (Knights, 2015). Ionizing radiation damages DNA by inducing single- and double-
strand DNA breaks and introducing genetic changes that can lead to cancer (Knights, 
2015).  
1.2.5 Allergies and Atopic Disease  	
There has been some inconclusive evidence that indicates allergies may have a 
protective effect against glioblastoma via a heightened immune system. Studies by 
Ostrom et al. have shown elevated IgE (>100 kU/L) significantly reduced glioma risk; the 
data for glioblastoma was not significant.  
1.2.6 Cellular Phones 	
The International Agency for Research on Cancer (IARC) published a study in 
2011 showing no correlation between cell phone usage and glioma risk (Ostrom et al., 
2014). In more recent years two cohort studies and three incidence rate over time studies 
have shown no significant risk of developing glioblastoma with cell phone use (Ostrom et 
al., 2014) However, one small case-control study did show significant data supporting a 
link between cell phone use and glioblastoma (Ostrom et al., 2014). Results remain 
inconclusive and further data is being generated on this topic.  
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1.3 Tumor Grading and Pathology  
1.3.1 Classical Presentation 	
Glioblastoma multiforme is an outmoded term that hints at the heterogeneity of 
glioblastoma. Glioblastoma is thought to be initiated by stem cell-like populations of 
cells that also promote its rapid migration (Knights, 2015). Though glioblastoma migrates 
swiftly, the majority are supratentorial and do not metastasize outside of the central 
nervous system. Typically glioblastoma is considered a Grade 4 malignant astrocytoma, 
but histogenesis is unclear, and there can be differentiated cells within the same tumor 
(A. L. Cohen & Colman, 2015). Uncontrolled proliferation, diffuse infiltration, 
propensity for necrosis, robust angiogenesis, intense resistance to apoptosis, and genomic 
instability are all hallmark traits of glioblastoma. On histological cross sections one can 
observe the heterogeneity of glioblastoma through the greyish-white tumor, the necrotic 
yellow regions, and red-brown discoloration from hemorrhage (Urbańska et al., 2014). 
Also notable is the dense hyperchromatic nucleus that is indicative of rapid cell 
proliferation. However, glioblastoma can be difficult to distinguish from normal tissue 
because of its ability to assimilate and infiltrate into healthy tissue (Urbańska et al., 
2014).  
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Figure 3. Histology of Glioblastoma. Glioblastoma diagnosis is dependent on 
identification of cellular pleomorphism with presence of mitotic figures, and 
glomerular structures as seen in this figure. Typically present is tumor cell 
necrosis, usually at the center of the tumor. (Ray-Chaudhury, 2010) 
 
1.3.2 Tumor Grading 	
Glioblastoma is currently classified as either the more prevalent primary 
glioblastoma or as secondary glioblastoma. Secondary glioblastomas progress from a 
lower grade tumor, commonly a low-grade astrocytoma (II) or an anaplastic astrocytoma 
(III); these make up only 5% of glioblastomas (A. L. Cohen & Colman, 2015). Secondary 
glioblastomas are more likely to have Isocitrate Dehydrogenase -1 or -2  (IDH1 or 2), or 
p53 mutations (A. L. Cohen & Colman, 2015). Primary glioblastomas, on the other hand, 
present as grade IV tumors at diagnosis (A. L. Cohen & Colman, 2015). They are 
typically found in older patients and present with increased EGFR gene expression (A. L. 
Cohen & Colman, 2015).  
Figure 2. Horizontal Section of 
Glioblastoma Pathology. This 
image demonstrates the necrotic and 
hemorrhagic nature of glioblastoma. 
(Ray-Chaudhury, 2010)  
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Figure 4. Divergent Signaling in Glioblastoma. An example of the mutated pathways that contribute to the 
development of primary or secondary glioblastoma. (Carrabba, Mukhopadhyay, & Guha, 2010) 
 
Figure 5. Histology of Differential Brain Tumors. Figure highlights the histological differences during the 
progression to secondary glioblastoma.(Al-Hussaini, 2013).  
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1.3.3 Classification of Adult High Grade Gliomas via Gene Expression 	
The Cancer Genome Atlas (TCGA) has identified four subgroups based on 
transcriptional profiling The first of the subgroups is proneural, which is the classic 
presentation in secondary glioblastoma (A. L. Cohen & Colman, 2015). Classical 
glioblastomas present with enhanced EGFR expression, most commonly EGFRvIII (A. 
L. Cohen & Colman, 2015). The third subgroup is mesenchymal; these tumors are likely 
to present with amplified MET and NF1 mutation, increased angiogenesis, hypoxia, and 
inflammatory response, and mesenchymal tumors are generally associated with poorer 
prognosis (A. L. Cohen & Colman, 2015; Kahlert et al., 2012). The fourth subgroup is 
neural, and is not well studied (A. L. Cohen & Colman, 2015).  
1.4 Current Methods of Diagnosis 
1.4.1 Clinical Presentation 	
The clinical presentation of glioblastoma is vastly dependent on the location and 
size of the tumor, but normal manifestations include aphasia (language problems), 
paresthesia (tingling), hemiparesis (weakness of one side of the body), and visual 
disturbances (Preusser et al., 2011). Also typical of glioblastoma patients are 
mood/personality changes, increased intracranial pressure, nausea, vomiting, headaches, 
and seizures (Preusser et al., 2011). Headaches are the typical indication, present in about 
50% of patients (Omuro A & DeAngelis LM, 2013). Not to be confused with benign 
headaches, the presence of a brain tumor can be differentiated by rapid onset in patients 
older than 50, nonspecific pain pattern, unilateral localization, and increasing intensity 
(Omuro A & DeAngelis LM, 2013). It is also necessary to rule out other syndromes that 
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imitate glioma symptoms; these include brain abscess, subacute stroke, multiple sclerosis, 
and other inflammatory diseases of the brain (Omuro A & DeAngelis LM, 2013).  
1.4.2 Magnetic Resonance Imaging (MRI) 	
MRI is the primary method of diagnosis; the images are usually enhanced with 
Gadolinium contrast (Omuro A & DeAngelis LM, 2013). Diffuse Tractor MRI-Based 
Tractography is a useful tool that utilizes the diminished amount of water present in 
myelinated white matter tracts to locate these areas, making it easier to avoid them in 
surgery (Ohue, Kohno, Kumon, & Ohnishi, 2014).  
 
Figure 6. Imaging Examples of Glioblastoma. From left to right: T1-weighted, gadolinium-enhanced MRI; T2-
weighted MRI; 18F-fluoro-ethyl-tyrosine (FET) amino acid PET. (Weller et al., 2015).  
1.4.3 CT Scan 	
CT scans are a less popular option for imaging glioblastoma, but are necessary for 
patients who cannot undergo MRI for reasons such as having a pacemaker (Omuro A & 
DeAngelis LM, 2013).  
1.4.4 Positron Emission Tomography (PET) Scan 	
PET scans use radioactive tracers to examine tissues and organs. Radioiodinated 
poly(ADP-ribose) polymerase 1 (PARP1) is a biomarker overexpressed in glioblastoma 
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tissue and is expressed at low levels in the healthy brain (Salinas et al., 2015). Salinas et 
al. developed a novel selective tracer 12-PARPi to aid in the imaging of tumors. 18F-
fluoroethyl-ʟ-thyrosine (FET) PET is a radiopharmacore used clinically to image gliomas 
(Buchmann et al., 2016). FET is extremely useful as a predictive metabolic agent, and 
was found to be even more sensitive than MRI at detecting residual tumor post-resection 
(Bénard, Romsa, & Hustinx, 2003; Buchmann et al., 2016).  
On the horizon of glioblastoma imaging is a chlorotoxin purified from scorpion 
venom. [131I]-radiolabeled versions are in clinical trial, and it is thought that this 
compound is particularly applicable to gliomas because the mechanism potentially 
involves binding of matrix metalloproteases secreted by gliomas (Le Roux & 
Schellingerhout, 2014). Optical labeling techniques like those mentioned are exciting 
developments for delineating tumors from healthy brain tissue.  
1.4.5 Blood Biomarkers 	
Blood biomarkers allow physicians to detect certain cancers solely through 
circulating proteins in the blood. Biomarkers have been established for many cancers; for 
example, the prostate specific antigen CA15-3 which is indicative of prostate cancer ( 
Preusser, 2014). Thus far, no circulating biomarkers have been discovered for 
glioblastoma, but Perez-Larraya et al. have recently suggested a combination of proteins 
that might be a useful diagnostic (Gállego Pérez-Larraya et al., 2014). Glial fibrillary 
acidic protein (GFAP) is an intermediate filament of astrocytes; high levels of expression 
were found in 20% of glioma patients. Chitinase-3-like protein 1 (YKL-40) is a 
glycoprotein secreted by many cell types. YKL-40 is secreted at high levels in 
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glioblastoma patients, but is also amplified in a multitude of other diseases, and is 
therefore potentially useful as a diagnostic in coordination with elevated GFAP levels. 
Insulin-like growth factor binding protein 2 (IGFBP-2) has also been identified as a 
prognostic marker in cancer. The profile of all three of these circulating proteins could 
potentially give a reliable glioblastoma diagnosis.  
1.5 Prognosis Indicators & Treatment Options 
1.5.1 Karnofsky Performance Status 	
The Karnofsky Performance Status (KPS) is a scale assessing the mental status of 
a patient, and is used in glioblastoma as a principal indicator of the severity of the tumor 
and symptoms. This scale includes 11 positions, and ranges from no evidence of disease 
(100 points) to complaints of forgetting location of objects, to death (0 points). It is 
currently the most powerful clinical prognostic factor representing the mental health of a 
patient (Swagerty & Johnson, n.d.; Urbańska et al., 2014).  
1.5.2 Histological Subtyping with Genomic Analysis 	
Histological subtyping aids physicians in determining the heterogeneity of 
glioblastoma tumors and is beneficial in predicting overall survival and deciding the best 
avenue of patient-specific treatment. One common prognostic marker is O6-
Methylguanine-DNA-methyltransferase (MGMT) methylation. MGMT is a DNA repair 
protein, which when expressed can repair DNA damage caused by temozolomide. 
MGMT is methylated in 30-35% of glioblastoma patients and its methylation is 
characteristic of longer overall survival (Rudà et al., 2015). MGMT methylation is also of 
predictive value, i.e. it is useful in choosing how to treat a patient; in the elderly, MGMT 
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promoter unmethylated tumors have shown to have no survival benefit in undergoing 
chemotherapy in coordination with radiation (Rudà et al., 2015). Isocitrate 
dehydrogenase 1 or 2 (IDH1 or 2) gene mutations are present in 5% of primary 
glioblastomas and >50% of secondary glioblastomas (Rudà et al., 2015). IDH1 mutated 
tumors are thought to represent a related but histologically distinct class of glioma. The 
mutated enzyme has the ability to produce 2-hydroxyglutarate (2HG), and is prognostic 
of increased survival compared with wild-type IDH1 expressing gliomas (Amelot et al., 
2015). 2HG is thought to promote oncogenic behavior through targeting specific enzymes 
involved in DNA methylation (Amelot et al., 2015).  
1.5.3 Symptomatic Treatment 	
Peritumoral edema may be the root of many symptomatic presentations; moderate 
relief may be provided by administering corticosteroids  (Omuro A & DeAngelis, 2013). 
The most popular choice of corticosteroid is Dexamethasone because of its low 
mineralocorticoid activity, but side effects can still be substantial (Omuro A & DeAngelis 
LM, 2013). It is pertinent to monitor the patient for primary CNS lymphoma (PCNSL) 
before administering corticosteroids as these drugs are lympholytic (Omuro A & 
DeAngelis LM, 2013). In cases where the patient presents with seizures, the use of 
antiepileptic drugs is necessary; Levetiracetam is preferable because it can work 
synergistically with chemotherapeutic agents (Omuro A & DeAngelis LM, 2013).  
1.5.4 Surgical Resection 	
Surgery is typically the initial line of treatment, but because of the delicate 
location of tumors it is often impossible to completely resect (Preusser et al., 2011). Even 
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when complete macroscopic resection is an option, infiltrative cells make for 
extraordinarily high recurrence rates (Preusser et al., 2011). Surgery is commonly 
indicated even for patients with inoperable tumors to obtain stereotactic biopsies for 
histological analysis (Omuro A & DeAngelis LM, 2013).  
1.5.5 First-Line Adjuvant Treatment 	
Carmustine Polymer (Gliadel) wafers are often placed at the site of resection 
during surgery. These wafers are a biodegradable matrix implanted with bis-
chloroethylnitrosourea (carmustine) as an extended release carrier system (Venur, 
Peereboom, & Ahluwalia, 2015). There is no statistically significant difference in 
survival, but the results are still positive with a median of 13.5 months with wafers in 
comparison to 11.4 in placebo (Venur et al., 2015). However, use of carmustine wafers 
comes with increased risk of cerebrospinal fluid (CSF) leakage and intra-cranial 
hypertension (Venur et al., 2015). Additional radiotherapy in combination with 
chemotherapy is the usual course of action. Radiotherapy is commonly given in 60 Gy 
doses divided in 30 fractions (Venur et al., 2015). Temozolomide (TMZ) is a relatively 
new inclusion to the protocol for glioblastoma. TMZ is a DNA alkylating agent 
commonly used to treat other cancers. TMZ given concomitantly with radiotherapy has 
increased median survival to 15 months from 12 months with radiotherapy alone, and the 
use of this agent is particular beneficial to patients with MGMT promoter methylation 
(Venur et al., 2015).  
1.5.6 Novel Therapeutic Targets 
1.5.6.1 Vascular Endothelial Growth Factor 	
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Glioblastoma is one of the most vascularized tumors, and is thus a great target for 
anti-angiogenic therapies.  Angiogenesis promotes upregulation of VEGF and tumors 
with high levels of VEGF are associated with rapid development and poor survival 
(Venur et al., 2015). Bevacizumab is a recombinant humanized monoclonal antibody 
against VEGF-A that demonstrated significant improvement in progression free survival 
(PFS) of 10.6 versus 6.2 months in combination with radiotherapy and TMZ, but didn’t 
change overall survival time. In a second Phase III trial, it didn’t have significant PFS or 
OS. Further research of Bevacizumab and other anti-angiogenic therapies such as 
Aflibercept are underway, but none have shown significant impact on patient survival 
(Venur et al., 2015).  
1.5.6.2 Integrins 	
 Integrins play a key role in cell substrate adhesion, and are therefore an ideal drug 
target to inhibit migratory tumor cells. Multiple trials have been performed using 
Cilengitide, an integrin inhibitor targeting αvβ3 and αvβ5 integrins. Cilengitide was 
adequately delivered to tumors, which can be an issue for glioblastoma, but didn’t elicit 
any results worth noting. For this reason Cilengitide is no longer being researched as 
treatment for high grade gliomas (Jordan & Wen, 2015).  
1.5.6.3 Tyrosine Kinase Inhibitors 
Tyrosine kinase inhibitors target receptor tyrosine kinases (RTKs) and are one of 
the most prominent anti-neoplastic therapeutic agents as these enzymes regulate signaling 
cascades controlling cell growth and survival (Jordan & Wen, 2015).  The most 
commonly amplified RTKs in glioblastoma are epidermal growth factor receptor 
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(EGFR), vascular endothelial growth factor receptor (VEGFR), and platelet derived 
growth factor receptor (PDGFR). EGFR is overexpressed in 40-90% of glioblastomas, 
and is thought to be a promising target, but results have been disappointing because of 
poor delivery across the BBB (Jordan & Wen, 2015; Venur et al., 2015). PDGFR is 
amplified or mutated in 10% of glioblastomas, but drug trials of the PDGFR inhibitor 
Imatinib showed a lack of efficacy, and trials of Dasatinib showed no significant benefit 
and adverse hematologic effects (Jordan & Wen, 2015). All tyrosine kinase inhibitors 
targeting VEGFR had no clinical benefits (Jordan & Wen, 2015).  
Signaling downstream of RTKs is often mediated through the PI3K/Akt/mTOR 
pathway. PI3K is an enzyme regulating cell survival and growth, and is commonly over 
activated in glioblastoma usually as the result of mutated PI3K genes, overactivation of 
RTKs, or loss of PTEN inhibition. Buparlisib and Px-866 (oncothyreon) were both well 
tolerated in phase I trials, but buparlisib was not efficacious in phase II trials and Px-866 
is currently undergoing trials. Everolimus and Temsirolimus (mTOR inhibitors) both 
showed toxicity when combined with TMZ and radiation (Jordan & Wen, 2015).  
Another downstream signaling cascade of RTKs is mediated through the GTPase 
Ras, and its pathway involving RAF/MEK/ERK protein kinases. Drugs targeting this 
pathway have difficulty penetrating the BBB and showed no significant improvement in 
patient outcome (Jordan & Wen, 2015).  
1.5.6.4 Isocitrate Dehydrogenase-1 and 2 	
Isocitrate dehydrogenase (IDH) is a metabolic enzyme that when mutated 
produces 2-hydroxyglutarate (2HG) as a byproduct; as discussed above this enzyme is 
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strongly implicated in secondary glioblastoma (Jordan & Wen, 2015). Drugs, such as 
AGI-5198 selectively inhibit this enzyme and deplete 2HG levels, which has been shown 
to slow tumor growth in vitro. This drug is currently in a Phase I clinical trial (Jordan & 
Wen, 2015). 
1.5.6.5 Histone Deacetylase (HDAC) 	
 Vorinostat (SAHA) is an anti-neoplastic agent commonly used to treat other 
forms of cancer such as cutaneous T-cell lymphoma. It is now undergoing research in 
glioblastoma, and is in Phase II studies. Vorinostat inhibits histone deacetylases, which 
prevents histones from being removed to enable gene transcription (Jordan & Wen, 
2015). One of the benefits of this drug is that it crosses the BBB, but there have been 
issues of thrombocytopenia in about 1/5 of patients (Venur et al., 2015). 
1.5.6.6 Proteasome inhibitors 	
Proteasomes breakdown unwanted proteins in healthy cells. When the proteasome 
is inhibited, the cell-cycle becomes dysregulated and apoptosis ensues, therefore drugs 
targeting the proteasome are an interesting target for cancer research (Jordan & Wen, 
2015). However, studies utilizing the proteasome inhibitor Bortezomib have not had 
promising results, partially because of limited BBB penetration (Jordan & Wen, 2015).  
1.5.6.7 Microtubules 	
Microtubules are dynamic components of the cell cytoskeleton, and are important 
in cell movement and as transport structures, as well as organization of cytoskeletal 
elements during mitosis. Inhibition of microtubule dynamics prevents cells from dividing. 
Paclitaxel has been tested with 35% of patients having improved disease, but because of 
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the generalized role of microtubules in cells, this drug is highly toxic (Jordan & Wen, 
2015). To limit the toxic side effects researchers conjugated Paclitaxel with L-glutamic 
acid to improve water solubility and target delivery, but in this study there was 
hematologic toxicity. To improve targeted delivery to the tumor and lower necessary 
dosage, Paclitaxel was then conjugated with Angiopep-2 and renamed ANG1005. 
ANG1005 employs LDL receptor-related protein 1 to cross the BBB adequately. Studies 
using ANG1005 showed good delivery, but similar toxicity profile to Paclitaxel in phase 
I trials, and phase II studies are ongoing (Jordan & Wen, 2015).  
1.5.7 Immunotherapy 
Immunotherapy is defined as any process that targets malignancy by harnessing 
the patient’s immune system. Typically, immunotherapy utilizes the patients’ cytolytic 
CD8+ T cells (CTLs) to bind class I major histocompatibility complexes (MHCs) 
displayed on antigen-presenting cells (APCs) and destroy the malignant tumor cells 
(Neagu & Reardon, 2015).  Because tumors are often immunosuppressive, especially in 
the case of gliomas, certain non-specific agents are also administered to boost immune 
processes. For example, interleukin-2 (IL-2) facilitates the clonal expansion of T cells 
(Neagu & Reardon, 2015). Interferons and toll-like receptor (TLR) agonists stimulate T 
cell activity also, through pro-inflammatory pathways (Neagu & Reardon, 2015). There 
are currently two categories of immunotherapy that elicit more specific responses. 
Passive immunotherapy has been successful in some cancer types because it is 
extraordinarily specific, and it relies on administering antibodies or immune cells not 
made by the patient to target an antigen expressed by the tumor (Neagu & Reardon, 
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2015). Passive immunotherapy is limited in that the tumor must express that specific 
marker, and therapy only lasts as long as treatment is continued (Neagu & Reardon, 
2015). Active immunotherapy utilizes the patient’s immune system to elicit a response, 
either by boosting insufficient responses or training the immune system to observe new 
targets (Neagu & Reardon, 2015). Active immunotherapy can have one or more targets, 
and cells will be trained to re-initiate an immunological response if prompted.  
 Applying immunotherapy techniques to gliomas is particularly challenging 
because the brain is fairly immunopriveleged being protected by the BBB (Bloch, 2015). 
The BBB under normal conditions is mostly impermeable to peripheral immune cells, 
and antigen recognition is monitored by microglia and astrocytes (Neagu & Reardon, 
2015). Gliomas develop extremely immunosuppressive environments; even when 
immune cells have invaded only 5-10% of them are T cells and the tumor is able to 
escape recognition by the peripheral immune system until it is very advanced (Neagu & 
Reardon, 2015). Vaccines are thought to be the best avenue to combat gliomas because 
they educate the immune system to target tumor-specific peptides instead of just 
stimulating nonspecific responses.  
1.5.7.1 Peptide Vaccines 	
Peptide vaccines deliver specific tumor peptides or tumor cell lysates to dermal 
APCs for uptake and display; this activates the CTLs to expand and elicit a response 
(Neagu & Reardon, 2015). Often this process is enhanced via immune stimulants such as 
keyhole limpet hemocyanin (KLH) or leukocyte growth factors such as GM-CSF or IL-2.  
	19 
30-40% of glioblastoma patients express a mutated EGFR, EGFRvIII, which is 
not expressed in other cells (Bloch, 2015). An antigenic vaccine for EGFRvIII conjugated 
to KHL has undergone and continues to undergo trials; the primary outcome measure of 
these trials was median PFS which increased for all trials. A phase III trial of EGFRvIII 
vaccine with adjuvant TMZ is underway (Neagu & Reardon, 2015). Other potential 
antigenic vaccines target Wilms Tumor (WT1) protein, surviving peptide, CMV antigens, 
and telomerase; this research is ongoing.  
One of the challenges of specific peptide vaccines is their use is limited to patients 
that express the target; in the case of EGFRvIII that is only 30-40% of patients. The 
heterogeneity of glioblastoma tumors poses another complication because when cells that 
express the target have been eradicated, other malignant cells may remain that facilitate 
tumor recurrence. To account for this researchers developed a multivalent vaccine by 
screening a large number of tumor samples and selecting 11 HLA-A2 synthetic tumor-
associated peptides (Neagu & Reardon, 2015). This vaccine demonstrated a positive 
immunologic response in 81% of HLA-A2 positive patients in a phase I trial and is 
undergoing further investigation (Neagu & Reardon, 2015).  
1.5.7.2 Dendritic Cell Vaccines 	
 Dendritic cell (DC) vaccines are far more personalized for the patient. In this 
approach the patient’s dendritic cells are extracted through plasmapheresis and pulsed ex 
vivo with a predetermined immune-stimulatory peptide (Neagu & Reardon, 2015). The 
activated DCs are now ensured to display the peptide on their cell surface and can 
stimulate an antigen specific T cell response on reintroduction into the patient. Early 
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phase clinical trials using this method have been reported with mixed results. For 
example the ICT-107 vaccine assimilates six HLA-A1/2 restricted peptides with DCs. 
This vaccine had an exceptional median PFS of 16.9 months in a small phase I study, but 
the placebo-controlled phase IIb trial didn’t show difference between placebo and 
treatment (Neagu & Reardon, 2015). Numerous studies developing patient-specific 
multivalent vaccines are in development and are highly awaited.  
1.5.7.3 Heat Shock Protein Vaccines 	
 Heat shock proteins (HSPs) are ubiquitously expressed, and are another route to 
deliver antigenic peptides to endogenous APCs. HSP complex 96 can be extracted from 
tumor cell lysates and has been utilized to express specific antigenic peptides on APCs 
(Neagu & Reardon, 2015). The single arm trial results using this method have been 
successful in increasing PFS, but more research is necessary.  
1.5.7.4 Immune Modulators 	
 As discussed above cancer, in particular glioblastoma, can be extremely 
immunosuppressive. The results of immunotherapy vaccines of all types in glioblastoma 
have procured results that extend PFS or OS by months, not years, and the resilience of 
glioblastoma and its ability to resist contribute greatly to this. Researchers are now 
exploring avenues to combat the ability of glioblastoma to escape the full immune 
response. CD4+ T cells are a subclass of regulatory T cells that produce cytokines the halt 
the effects of APCs and effector T cells (Neagu & Reardon, 2015). In the healthy 
individual these cells act as a checkpoint to ensure that the appropriate immune response 
is initiated. CD4+ T cells are enriched in the blood of glioblastoma patients, and have 
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therefore been suggested to contribute to the immunosuppressive environment (Neagu & 
Reardon, 2015). Patients with low levels of regulatory T cells have a greater humoral 
response to vaccination, and studies are ongoing to evaluate the results of these findings.  
Activation of effector T cells requires binding of its cofactor B7 with its receptor, 
also on the T cell. B7 binding to CD28 will activate the T cell and stimulate an immune 
response, but binding to CTLA-4 receptors will inactivate the T cell (Neagu & Reardon, 
2015). Inhibition of CTLA-4 receptors will prevent T cell inactivation and generate a 
robust immune response (Neagu & Reardon, 2015). Use of CTLA-4 inhibitors, such as 
ipilimumab, has been shown to improve the survival of melanoma patients, and trials 
have been initiated in glioblastoma patients (Neagu & Reardon, 2015).  
Programmed death ligand I (PD-L1) is a modulator of T cell activity that is 
expressed on a variety of immune cells. When bound to its receptor, programmed death I 
(PD-1), T cell apoptosis occurs (Neagu & Reardon, 2015). The expression of PD-L1 on 
cancer cells is a large factor of the immunosuppressive environment of tumors. Not only 
does PD-L1 expression contribute to local immunoresistance, but increased systemic 
PDL-1 contributes to a muted immune response that is tumor-independent. High 
expression of PD-1 on circulating monocytes in newly diagnosed glioblastoma patients 
has been linked to worsened survival. Trials of the PD-1 inhibitor nivolumab are ongoing 
in patients with recurrent glioblastoma (Neagu & Reardon, 2015). Currently there are no 
successful anti-invasive therapeutics, but as aforementioned there are some in 
development, and glycogen synthase kinase-3 (GSK-3) is a candidate for this research.  
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2. GLYCOGEN SYNTHASE KINASE-3 
2.1 Introduction and Structure 
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine (Ser/Thr) protein 
kinase that regulates a wide variety of substrates via phosphorylation at specific amino 
acids. GSK-3 has a wide range of functions, including regulation of glycogen 
metabolism, protein synthesis, cell proliferation, cell differentiation, microtubule 
dynamics, cell motility, cell-division cycle, transcription factors, and apoptosis. Such a 
large distribution of control has attributed GSK-3 dysfunction to the development of 
diseases such as diabetes, cancer, bipolar disorder, Huntington’s disease, and Alzheimer’s 
(Frame & Cohen, 2001; Rayasam, Tulasi, Sodhi, Davis, & Ray, 2009).  GSK-3 is unusual 
in being one of the few kinases that is constitutively active in cells, and is inhibited when 
phosphorylated. GSK-3 has two well-studied isoforms, alpha and beta, and they share a 
97% sequence homology within their kinase catalytic domains. GSK-3α has an extended 
N-terminal glycine-rich tail, and thus a higher molecular weight (Frame & Cohen, 2001). 
Though the two isoforms are not functionally redundant, there is overlap in certain 
pathways; for example both GSK-3α and GSK-3β contribute to axon development in 
hippocampal neurons (Rayasam et al., 2009).  
2.2 Regulation 	
As mentioned above, GSK-3 is inhibited via phosphorylation, but can also be 
regulated by cellular localization and protein-protein interactions. Unlike most enzymes, 
phosphorylation of GSK-3’s substrates usually leads to their inactivation (Frame & 
Cohen, 2001). GSK-3 contains a docking site for substrates that have been previously 
	23 
phosphorylated, or “primed”.  These primed substrates have a phosphate group added to 
the consensus sequence Ser/Thr-X-X-X-pSer/pThr with X being any amino acid and 
pSer/pThr being phosphorylated serine/threonine (Frame & Cohen, 2001). The priming 
phosphate then specifically recognizes and interacts with arginine96 (Arg96), Arg180, 
and Lysine205 (Lys205) in a binding pocket on GSK-3 (Rayasam et al., 2009). Aside 
from this binding pocket, substrate specificity is also seen through the requirement of 
Phenylalanine67 (Phe67), Glutamine89 (Gln89), and Asparagine95 (Asn95) to position 
the substrate for phosphorylation by GSK-3β (Rayasam et al., 2009). Some identified 
primed substrates of GSK-3 are glycogen synthase (GS), eukaryotic initiation factor 2B 
(eIF2B), and beta catenin. GSK-3 can also phosphorylate unprimed substrates such as 
cyclin D3, axin, adenomatous polyposis coli (APC), but this occurs less frequently 
(Rayasam et al., 2009).  
2.2.1 Regulation by insulin and Growth Factors 	
As previously mentioned, GSK-3 is inhibited by phosphorylation; this occurs at 
Ser21 for GSK-3α and Ser9 for GSK-3β. Once phosphorylated, it can act as a 
pseudosubstrate and bind in the pocket that would ordinarily interact with a phosphate 
group of a primed substrate (Rayasam et al., 2009).  
Insulin signaling will activate Akt/PKB, which inactivates GSK-3 via 
phosphorylation at the amino terminus. This will release GS of inhibition and induce 
glycogen synthesis. 
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Figure 8. Insulin Signaling Utilizing GSK-3. A classic representation of the insulin pathway and control of glycogen 
synthesis. (P. Cohen & Frame, 2001) 
Figure 7. Control of GSK-3. Regulation of GSK-3 highlighting the ability of the N-termnus phosphate to act as a 
pseudosubstrate and inhibit GSK-3. (P. Cohen & Frame, 2001) 
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GSK-3 is also phosphorylated at Ser21/Ser9 by AGC kinase, p70 ribosomal S6 
kinase (S6K1), p90 ribosomal S6 kinase. S6K1 is a potential mechanism inhibition of 
GSK-3 by amino acid availability (Frame & Cohen, 2001). Inhibition of GSK-3 also 
occurs via cAMP kinase mediated phosphorylation of Ser21/Ser9 (Frame & Cohen, 
2001).  
Another method of inhibition is phosphorylation at the carboxyterminus by p38 
mitogen-activated protein kinase (MAPK). This manner of inactivation occurs only for 
GSK-3β on Thr390, which is not present in GSK-3α, and occurs primarily in the brain 
and thymocytes (Rayasam et al., 2009; Thornton et al., 2008). Phosphorylation can also 
lead to stimulation of GSK-3. The kinases that perform this phosphorylation are not well 
characterized but the phosphorylation occurs at Tyr279 for GSK-3α and 216 for GSK-3β 
(Rayasam et al., 2009).  
2.2.2 Wnt Pathway Regulation 	
 The Wnt pathway was discovered using Wingless, the Drosophilia homolog of 
Wnt (P. Cohen & Frame, 2001). Implicated in embryonic development, researchers 
discovered that knockout or overexpression of this gene changed patterns of segment 
polarity in Drosophilia (Cohen & Frame, 2001; Rayasam et al., 2009). Wnt is also of high 
importance in cancer development and dysregulated gene expression through the 
regulation of stem cell biology. The Wnt pathway utilizes a different method of 
regulation, via sequestration of GSK-3 in a multiprotein complex including axin, beta-
catenin, and (APC) protein (Rayasam et al., 2009). Without a Wnt signal, GSK-3 actively 
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phosphorylates beta-catenin, and targets it via ubiquitylation for proteasome-mediated 
degradation (Rayasam et al., 2009). Inhibition occurs via the FRAT and DVL protein 
complex, which disrupt the interaction of GSK-3 and axin; and promote beta-catenin 
stabilization and nuclear translocation where it interacts with transcription factors 
lymphoid enhancer factor (LEF) and T cell factor (TCF). This promotion of transcription 
factors activates target genes like c-myc and cyclin D1 and increases cell proliferation, 
explaining the role of this pathway in cancer development (Rayasam et al., 2009).  
 
Figure 9. Wnt Signaling Pathway. A clear image showing the canonical Wnt pathway and the role of GSK-3. (P. 
Cohen & Frame, 2001). 
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2.3 Implication in Glioblastoma 	
The role of GSK-3 in cancer cell migration is a subject with conflicting sides. 
Some research has suggested GSK-3 inhibition promotes cancer cell migration via 
epithelial to mesenchymal transition (Nowicki et al., 2008). However, GSK-3 inhibition 
has also been shown to inhibit tumor invasion, and several of its well-known substrates 
(paxillin, FAK, NFκB, β-catenin, and SNAIL) have roles in cell migration (Nowicki et 
al., 2008). It is thought that GSK-3 is regulated via localization in distinct subcellular 
pools, which may explain the conflicting data. In studies performed by Nowicki et al. 
GSK-3 inhibition via lithium halts glioma invasion. Research has also shown that healthy 
brain tissue expresses lower levels of GSK-3β, and that inhibition of GSK-3β reduces 
glioma proliferation, and has protective benefits for brain tissue. GSK-3β inhibition also 
activated tumor suppressor genes p53 and p21, as well as decreased levels of Rb 
phosphorylation leading to apoptosis (Miyashita et al., 2009). Studies also show that 
GSK-3β inhibition stabilizes PTEN, which will arrest the cell cycle and promote 
glioblastoma cell proliferation (Miyashita et al., 2009).  
Research by Williams et al. demonstrates that GSK-3 inhibitors of the indirubin 
family successfully inhibit glioblastoma invasion at a 4,000 fold lower concentration than 
LiCl, and the use of these indirubins does not exhibit high toxicity. Indirubins were 
discovered through a Chinese medicine Dang Gui Long Hui Wan, and were primarily 
investigated as anti-leukemia agents that function to inhibit angiogenesis (Kim, Shin, 
Kang, & Park, 2011). The work of Williams et al. examined three indirubins, 6-
bromoindirubin-oxime (BIO), BIA (6-bromoindirubin-acetoxime), and indirubin 3’-
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oxime (IO). These three indirubins showed a more robust inhibition of GSK-3 than 
previously observed using LiCl, as indicated by a reduced phosphorylation of β-catenin. 
This research shows that GSK-3 inhibitors, and more specifically indirubins, are viable 
candidates for anti-invasive therapies for glioblastoma.  
2.4 Research Question 	
Studies utilizing LiCl and indirubins to inhibit GSK-3 and prevent tumor cell 
migration have demonstrated varying levels of success, but have shown promise in 
application to glioblastoma. Recently, a number of more selective GSK-3 inhibitors have 
been developed, and we investigated their anti-invasive properties to examine whether 
GSK-3 is a good target. BIO was included in our panel of GSK-3 inhibitors; this 
compound inhibits GSK-3 with an IC50 of 5 nM, and also has some effects on cyclin 
dependent kinases ( >16-fold selectivity over cyclin-dependent kinase 5 (CDK5)), as well 
as targeting the pan-JAK pathway (“BIO | GSK-3 inhibitor | Read Reviews & Product 
Use Citation”). BIO interacts with the ATP-binding pocket of these kinases (“BIO | GSK-
3 inhibitor | Read Reviews & Product Use Citation”). CHIR-99021 (CT99021) is another 
GSK-3 inhibitor in common use, but is more selective than BIO and does not exhibit 
cross-reactivity against CDKs (“CHIR-99021 (CT99021) | GSK-3 inhibitor | Read 
Reviews & Product Use Citation”).  The newest developed GSK-3 inhibitor in our panel, 
AZD1080 is highly selective for GSKα/β with no other known targets (“AZD1080 | 
GSK-3 inhibitor | Read Reviews & Product Use Citation”). The fourth GSK-3 inhibitor 
utilized is AZD2858; a selective inhibitor which activates Wnt signaling (“AZD2858 | 
GSK-3 inhibitor | Read Reviews & Product Use Citation”). This study aims to 
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characterize the anti-invasive properties of these four GSK-3 inhibitors in four glioma 
cell lines using three assays in hopes of providing evidence to guide their future clinical 
application. Our hypothesis is that highly selective inhibitors of GSK-3 will allow us to 
understand better the suitability of GSK-3 as a target in the treatment of glioblastoma.  
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METHODS  
1. Cell Lines & Chemicals  	
Human glioblastoma cell lines U251 and U1242 from ATCC, and G9, and G30 
obtained from Ohio State University (OSU), were utilized throughout this study. 
Established protocols, approved by the Institutional Research Board, were used by the 
OSU tissue procurement facility to acquire human tissue.  
Marker vector copGFP (System Biosciences, empty pCDH lentiviral vector) was 
transfected into U251, G9, and G30 cell lines to be utilized for imaging. RFP- lpp-hluc-
lv-206-025-c (Genecopeia) was utilized for U1242 imaging.  
 U251 and U1242 were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) (Invitrogen,Carlsbad, CA, USA) with the addition of 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin. G9 and G30 cell lines were cultured in 
Neurobasal medium (Life Technologies, Grand Island, NY, USA) and supplemented with 
b27, epidermal growth factor (EGF), fibroblast growth factor (FGF), and without Vitamin 
A. EGF and FGF were given at 10ng/mL and obtained from Peprotech (Rocky Hill, NJ, 
USA). All cells were sustained in culture at 37ºC with 5% CO2.  
 Dimethyl Sulfoxide (DMSO) was used as a solvent for all compounds and a 
negative control for all assays. CHIR99021, BIO, AZD1080, and AZD2858, known 
GSK-3 inhibitors, were obtained from Tocris and tested in all assays.  
2. Transwell (Boyden Chamber) Assay 	
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24-well plates with 8µm or 3µm pore size inserts (ISC Bioexpress, Kaysville, UT, 
USA) were coated with 50µl of 10µg/ml Fibronectin in phosphate-buffered saline (PBS). 
U251, U1242, G9, or G30 cells grown in DMEM supplemented with 10% FBS and 1% 
penicillin-streptomycin were counted and allotted at 50,000 cells /well to be incubated 
with either 10µm or 1µm of the selected treatment (DMSO, CHIR99021, AZD1080, 
AZD2858, BIO) for three hours. The bottom chamber of the plate was washed and 
medium with drugs was added. Cells were transferred to the insert and permitted to 
migrate for a minimum of twelve hours while being monitored using a Nikon TE2000 
microscope system with on-stage incubation for live-cell imaging.  
3. Collagen Spheroid Assay 		 	
For three-dimensional spheroid cultures, 1,000 cells were cultured in 96-well ultra 
low attachment plates in either DMEM with 10% FBS and 1% penicillin-streptomycin 
(U251 and U1242 cell lines) or neurobasal medium with growth factors and b27 (G9 and 
G30 cell lines). After spheroid/aggregate formation, the medium was partially removed 
(10µl leftover) and supplemented with liquid 40µl neutralized collagen I solution 
(PureCol, Inamed, Fremont, CA, USA). The medium was removed and replaced with 
300µl neutralized collagen I solution (PureCol, Inamed, Fremont, CA, USA). Collagen 
was neutralized to pH 7.5 using 1N NaOH and fortified with .5X DMEM for U251 and 
U1242 cell lines and .5X neurobasal medium for G9 and G30 cell lines. The collagen I 
solution was allowed to polymerize into a gel at 38ºC. Medium (50µl) with drugs (2x 
concentration) was added on top of the collagen I. Spheroid expansion was monitored up 
to 96 hours using a Nikon TE2000 microscope system with on-stage incubation.  
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4. Wound Healing (Scratch) Assay 	
Cells were seeded at 20,000/well on a 48-well plate and allowed to grow in 
DMEM media with 10% FBS and 1% penicillin-streptomycin until a monolayer was 
formed. Drugs were added and wells were scratched using a 200µl pipet tip (100-300µm 
gap). Microscopic visualization was done over a period of 24 hours using a Nikon 
TE2000 or Nikon Eclipse Ti, both with on-stage incubation.  
4.1 ATP Luciferase Reporter Assay for Cell Death 	
After the scratch assay, medium was removed and cells were lysed using the 
Steady-Glo Luceriferase Assay System (Promega), which provides Luciferase and 
substrate D-luciferin. A limiting factor for signal strength is ATP from analyzed cells. 
Light output of luciferase was detected using Fluostar Optima plate reader (BMG 
Labtech, Durham, NC).  
5. TCF-LEF Luciferase Reporter Assay 	
M50 and M51 (M50-pTA/Super8XTOPflash-β-catenin binding; M51-
pTA/Super8XFOPflash- β-catenin NoBinding) plasmids were provided by Dr. Randall 
Moon, University of Washington, Seattle, WA. Plasmid DNA was isolated from DH5α 
bacterial cultures. The sequence 8xTCF-LEF-TA (TCF-LEF sequence allowing binding 
of TCF-LEF transcription factor, TA-minimal eukaryotic promoter) was chosen from the 
pTA plasmid to be inserted and cloned into pGL4.14 plasmid (Promega).  
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The plasmid DNA was isolated from 5mL cultures using the PureLink Quick 
Plasmid Miniprep Kit (Invitrogen, Carlsbad, CA, USA). Bacterial cultures were spun at 
6000 rpm for 10 minutes; pellets were then re-suspended in buffer (50mM Tris-HCL, pH 
8.0, 10mM EDTA) before being applied to the column. Lysis was performed using an 
alkaline/SDS procedure (200mM NaOH, 1% w/v SDS) and the lysate was applied to a 
silica membrane spin column that selectively binds plasmid DNA. Wash buffer was 
applied to remove contaminants, and the plasmid DNA was eluted in preheated TE 
Buffer (10mM Tris-HCL, pH 8.0, .1mM EDTA). A microcentrifuge at room temperature 
was used for all procedural steps and spun at >12,000 x g.  
Restriction enzymes HindIII-HF (sticky ends, high-fidelity) and SacI (sticky ends) 
(New England BioLabs Inc.) were employed to cut purified pTA plasmids. pGL4.14 
(Promega) provided the plasmid vector for new construct, also having been cut with 
HindIII-HF and SacI restriction enzymes.  
Next a mixture of 1µg of DNA plasmid obtained from the PureLink Quick 
Plasmid Miniprep Kit (Invitrogen), 1.0µL of NEBuffer 2.1 (New England BioLabs Inc.), 
0.5µL of HindIII and SacI, and 7µL of deionized water were digested in a 37ºC water 
bath for 1 hour.  
The digested nucleic acids were mixed with loading buffer (20% Ficoll 400, 0.1M 
Na2EDTA, pH 8, 1.0% sodium dodecyl sulfate, 0.25% bromphenol blue, 0.25% xylene 
cyanol) and run on 1% agarose/ethyl bromide/1xTAE gel. 1µg Ready load 1kb DNA 
ladder (Invitrogen) was run as a standard. The gel was run at 5 volts per cm of tank 
length (150V), and visualized using a BioRad ChemiDoc XRS. The chosen vector and 
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insert were cut out of the gel and purified using the protocols of the PureLink Quick Gel 
Extraction Kit (Invitrogen).  
Protocols established in the Quick Ligation Kit (New England BioLabs Inc.) were 
used to ligate purified insert vector. Bacteria (DH5α competent E.Coli) were plated 
overnight with 1.0µL of the ligation mixture. Colonies were then expanded to 5ml liquid 
culture and DNA was isolated using the PureLink Quick Plasmid Miniprep Kit 
(Invitrogen). The same restriction enzymes, HindIII and SacI, were used to cut DNA to 
determine if our fragment had been inserted. The cloning procedure indicated two new 
DNA constructs, named: pGL4.14/Super8XTOPflash or pGL4.14/8xTCF-LEF-TA- β-
catenin-Binding and pGL4.14/Super8XTOPflash or pGL4.14/9xTCF-LEF-TA- β-
catenin-NO-Binding.  
The established procedure of the PureLink HiPure Plasmid Filter Maxiprep Kit 
(Life Technologies) was used, included the suggested scaling up of plasmid DNA 
purification. The plasmids were introduced to G9 glioma cells using the Lipofectamine 
3000 reagent. The stable clones were selected using Hygromycin B (150µg/mL, Life 
Technologies). The G9/pGL4.14/8xTCF-LEF-TA- β-catenin-Binding cells were plated in 
96-well white wall plates, 10,000 cells/well, in 84 wells.  
CHIR99021, AZD1080, AZD2858, and non-treated cells were incubated with 
cells for 6 hours to allow TCF-LEF-TA-dependent accumulation of Luciferase. Medium 
was removed and cells were lysed using the Steady-Glo Luciferase Assay System 
(Promega), which also provides the luciferin substrate. Light output reflects promoter 
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activity, and was determined using Fluostar Optima plate reader (BMG Labtech, Durham, 
NC).  
6. Immunohistochemistry 	
G9 cells were cultured on 8-chamber Lab-Tek glass slides, and treated with 
CHIR99021, BIO, AZD1080, AZD2858 and control DMSO all at 10µm for 6 hours. 
Cells were washed with ice-cold DPBS (Dubecco’s Phosphate Buffered Saline, Life 
Technologies) and fixed using 4% paraformaldehyde solution and washed with DPBS 
supplemented with .1% Triton X-100 (Sigma-Aldrich). Normal donkey serum was used 
to block (non-immunized, Jackson ImmunoResearch, West Grove, PA). Primary 
antibody, mouse anti-beta-catenin (1:500) (Cell Signaling) was added and slides were 
incubated overnight at 4ºC. Cells were washed multiple times using a DPBS-Triton X-
100 solution, and fluorescent labeled secondary antibody (488nm Alexa Fluor anti-
mouse, 1:1000; Jackson ImmunoResearch) was incubated with cells for 6 hours to be 
utilized for visualization. Cells were repeatedly washed with the DPBS-Triton X-100 
solution, and images were produced with a ZEISS LSM710 confocal microscope.  
7. Statistical Analyses 	
 All image processing was performed using ImageJ (Schindelin, 2015), and all 
statistical analysis was done in Microsoft Excel 2010.  
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RESULTS 
As formerly stated, GSK-3 inhibitors have proven to be potential therapeutic 
agents for glioblastoma. However, the GSK-3 inhibitors used in these previous studies 
were not selective, and inhibit other kinases in addition to GSK-3. Therefore, we have 
investigated newer highly selective GSK-3 inhibitors, which allows a more precise view 
of how they function in a variety of assays, and provides valuable information for future 
use. We utilized four gliomas cell lines in three differential assays to garner information 
on the suitability of GSK-3 as a drug target, and to hypothesize about how its inhibition 
may prevent glioblastoma cell invasion.  
1. BIOLOGICAL EFFECTS OF GSK-3 INHIBITION 
1.1 A luciferase reporter to show the upregulation of beta-catenin, a hallmark of GSK-
3 inhibition 
Firstly it was important to confirm that GSK-3 was indeed being inhibited by our 
specific inhibitors: CHIR99021, BIO, AZD1080, and AZD2858 (utilizing DMSO as 
control). This was accomplished with the U251 cell line, using the TCF/LEF-luc assay as 
discussed in methods. The inhibition of GSK-3 promotes nuclear localization of β-
catenin, which acts as a transcription factor and promotes formation of luciferin (P. 
Cohen & Frame, 2001; “TCF/LEF Reporter”). Here it was shown that GSK-3 inhibitors 
CHIR99021, AZD1080, and AZD2858 demonstrated a dose-dependent increase in β-
catenin expression. The largest increase in expression was found in cells treated with 
AZD1080, but notably AZD2858 maintained a high signal at lower drug 
 
	37 
concentrations. CHIR99021 and AZD1080 maintained a signal until a concentration of 
about 1.25µM, whereas AZD2858 inhibited GSK-3 signaling at about 0.3µM. 
Figure 10. U251pGL-B, TCF/LEF-luc activity in the presence of GSK-3 Inhibitors. Strong luminescent signals 
were obtained at high concentrations of CHIR99021, AZD1080, & AZD2858 indicating a high level of GSK-3 
inhibition. AZD2858 continued to maintain luminescence at lower concentrations than CHIR99021 & AZD1080. 
1.2 Immunohistochemistry 	
β-catenin is a well-studied substrate of GSK-3 involved in regulation of cell 
junctions, and is also of particular importance as a transcription factor (P. Cohen & 
Frame, 2001). β-catenin therefore has many implications and a wide range of effects; its 
localization plays an important role in its functions. Typically the inhibition of GSK-3 
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prevents the ubiquitin-mediated proteolysis of β-catenin, allowing its translocation into 
the nucleus where it regulates gene transcription. However, this is a complex pathway, 
and the sequestration of β-catenin into differential pools can produce a variety of results 
(P. Cohen & Frame, 2001). Nonetheless, the upregulation of β-catenin transcriptional 
activity can be used as an indication of inhibition of GSK-3, and the effect of our GSK-3 
inhibitor panel over a range of concentrations produced a varying level of β-catenin 
increase in glioblastoma cells.  
We utilized immunostaining techniques to show the β-catenin upregulation in G9 
cells. Cells were fixed and stained for β-catenin 6 hours after drug treatment, and the 
experiment was also performed 24 hours after drug treatment. Our results indicated that 
CHIR99021 and AZD1080 produced the highest levels of β-catenin upregulation, but all 
drugs demonstrated a significant increase compared with DMSO controls.  
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Figure 11. Immunostaining of β-catenin in Glioblastoma G9 cells. Immunostaining techniques were used to indicate 
the upregulation of β-catenin seen via the prevention of ubiquitin-mediated proteolysis of initiated by inhibition of 
GSK-3. 
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2. CELL INVASION ASSAY 
The transwell assay, also known as the Boyden chamber assay, is used to quantify 
the migration of cells through a porous membrane. In this technique, cells are seeded in 
an upper chamber and must intercalate through pores to a bottom compartment. This 
assay is useful because the size of the pores can be controlled to mimic the environment 
in the brain through which the cells must migrate. We first tested 3µM and 8µM pores; 
which are comparable to the in vivo environment. After success in both 3µM and 8µM, it 
was decided to continue with 8µM membranes; it was assumed if migration could be 
prevented in a model that is easier to move through than its application then results could 
be reproduced in the brain. Quantification involved counting the cells that have invaded 
the bottom compartment. 
CHIR99021 inhibited glioma cell migration in a dose-dependent manner in 3/3 
cell lines. Results were replicated three times in U251pCDH with both 3µM and 8µM 
pores, and twice in G9. AZD1080 was efficacious in 3/3 cell lines also, with only 1µM 
not showing significant data in G9. AZD2858 also had concentration-dependent 
significant data in 3/3 cell lines, with the exception of 10µM in U1242 cells. BIO also 
proved to be a potent inhibitor of migration in 3/3 cell lines. In three of the four cell lines 
treated cells migrated through the pores significantly less, with the fourth cell line, G30, 
unable to migrate under any conditions.  
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Figure 12. Area of GSK-3 Inhibitor CHIR99021 Treated U251pCDH, G9pCDH, & U1242 Glioblastoma Cell 
Lines as Seen in an 8µM Transwell Assay. 
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Figure 13. Area of GSK-3 Inhibitor BIO Treated U251pCDH, G9pCDH, & U1242 Glioblastoma Cell Lines as 
seen in an 8µM Transwell Assay. 
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Figure 14. Area of GSK-3 Inhibitor AZD1080 Treated U251pCDH, G9pCDH, & U1242 Glioblastoma Cell Lines 
as Seen in an 8µM Transwell Assay.  
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Figure 15. Area of GSK-3 Inhibitor AZD2858 Treated U251pCDH, G9pCDH, & U1242 Glioblastoma Cell Lines 
as Seen in an 8µM Transwell Assay. 
3. WOUND HEALING ASSAY (SCRATCH) 
The transwell assay measures chemotactic behavior; to test haptotactic behavior 
we used another migration assay. A wound-healing scratch assay was performed by 
scratching a monolayer of cells and analyzing the gap area after treatment and 24 hours in 
comparison with the initial area. The results of this assay were less promising; the drugs 
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did very little to prevent the closure of the scratch. Most successful of the treatments in 
majority of the cell lines was BIO, but no data was significantly different from DMSO.   
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Figure 16. Area of Scratch and Consequently ATP Levels in G30pCDH, G9pCDH, and 
U1242 Cell Lines respectively, treated with GSK-3 Inhibitors BIO, CHIR99021, 
AD1080, AZD2858, and control DMSO.  
 
 
 
4. CELL VIABILITY (ATP) 
After performing the wound-healing assay, treated cells were then utilized for a 
cell viability assay. It was necessary to determine whether the effects of CHIR99021, 
AZD1080, AZD2858, and BIO influenced glioma cell migration and not only cell 
viability. The ATP assay is a relatively simple method that images via luminescence the 
primary energy currency of cells, ATP, and in our case to thus determine the viability of 
the cells. Our results show that GSK3 inhibitors were not killing the cells, even at high 
drug concentrations of 10µM. The amount of luminescence produced by cells treated 
with drugs was comparable to the amount produced by the positive control and cells that 
received no treatment at all, indicating cells are alive, and their viability was not affected 
under the experimental conditions.  
5. PROLIFERATION AND INVASION (SPHERES)  
For the final migration assay we employed a 3-D assay where glioma spheroids 
were implanted in a type I collagen matrix. This is a profitable assay, in particular for 
studying cancer invasion, because the spheroid mimics a cell-dense core of a tumor, and 
cells invade outwards mimicking brain tumor invasion while employing process 
extension and matrix remodeling. The most successful GSK-3 inhibitor in this assay was 
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BIO, which showed concentration-dependent inhibition of invasion in 4/4 cell lines 
tested. For the remaining drugs tested, results were cell line dependent. U1242 appeared 
to be the most sensitive cell line tested; AZD2858 prevented invasion at all 
concentrations, but CHIR99021 and AZD1080 were only successful at high drug 
concentrations. AZD2858 inhibited collagen invasion at 10µM in U251, but AZD1080 
worked only at 20µM. CHIR99021 had very poor results in U251, and was tested 
multiple times with no success at any concentration. CHIR99021, AZD1080, and 
AZD2858 demonstrated a complete lack of inhibition of migration in G9 and G30 cell 
lines.   
Figure 17. Mask of Sphere Outgrowth in GSK-3 Inhibitor Treated U251pCDH Collagen Spheroids. Cells were 
allowed to migrate for 96 hours.  
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Figure 18. Quantitative Data for CHIR99021 Treated U251pCDH, G9pCDH, G30pCDH, and U1242 Collagen 
Spheroid Outgrowth. Cells were allowed to migrate for 96 hours, the X-axis indicates time, and the Y-axis shows 
area migrated.  
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Figure 19. Quantitative Data for AZD1080 Treated U251pCDH, G9pCDH, G30pCDH, and U1242 Collagen 
Spheroid Outgrowth. Cells were allowed to migrate for 96 hours, the X-axis indicates time, and the Y-axis shows area 
migrated.  
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Figure 20. Quantitative Data for AZD2858 Treated U251pCDH, G9pCDH, G30pCDH, and U1242 Collagen 
Spheroid Outgrowth. Cells were allowed to migrate for 96 hours, the X-axis indicates time, and the Y-axis shows area 
migrated.  
	51 
 	
Figure 21. Quantitative Data for BIO Treated U251pCDH, G9pCDH, G30pCDH, and U1242 Collagen Spheroid 
Outgrowth. Cells were allowed to migrate for 96 hours, the X-axis indicates time, and the Y-axis shows area migrated.  
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DISCUSSION 
 
Our results indicate that the panel of GSK3 inhibitors tested, CHIR99021, 
AZD1080, AZD2858, and BIO are viable candidates for anti-invasive glioblastoma 
treatment. Replicable, dose-dependent, significant success was had in 3/3 cell lines in the 
transwell assay testing all four drugs. This led us to hypothesize that GSK3 is potentially 
tied to the ability of glioblastoma cells to contract and intercalate through the pores of the 
membrane, whereas this motion was not procured by the other assays.  
Indeed, it was discovered that the application of this panel of GSK3 inhibitors in 
another assay performed by Nowicki et al. inhibited the contractile capability of HUVEC 
and HBMEM epithelial cells. Attempts were made to reproduce this assay utilizing the 
glioblastoma cell lines, but the setup was not technically feasible.  
Mixed results were produced in the collagen spheroid assay. It was clear that BIO 
was able to inhibit cellular invasion in the collagen matrix. The remaining drugs tested 
had some success at high concentrations in U1242 cells, and with the exception of 
CHIR99021, in U251. As stated above, no significant inhibition occurred in G9 or G30 
cells for CHIR99021, AZD2858, or AZD1080.  
Both GSK-3α and GSK-3β are implicated in a wide variety of pathways including 
Wnt, notch, tyrosine kinase, and G-protein coupled receptor signaling, and it is no 
surprise inhibition has been shown to have differential results. For example, lithium, a 
potent GSK3 inhibitor, has stimulated cell proliferation in mammary tumor cells, but 
inhibits proliferation in melanoma and hepatocellular carcinoma (Nowicki et al., 2008). 
Our results support the work of Williams et al. in that GSK3 inhibition blocks invasion in 
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the transwell assay, and that BIO is also capable of inhibiting cell invasion in a collagen 
spheroid assay. Our novel panel of drugs also demonstrated some success in the collagen 
spheroid assay, but no significant success in the wound-healing assay.  
Application of our panel of specific small molecule GSK3 inhibitors, BIO, 
CHIR99021, AZD1080, AZD2858, to the variety of assays tested shows that they should 
not be ruled out as potential therapies for glioblastoma. Given the extremely rapid onset 
and lethality of glioblastoma, with high recurrence and little progression in treatment 
options, there is a clear need for alternatives. We propose CHIR99021, AZD1080, 
AZD2858, and BIO have inherent potential to be anti-invasive treatment options for 
glioblastoma, and they importantly don’t exhibit cytotoxicity; supplemental research is 
implicated to further asses their suitability, with a particular focus on examining a 
potential relationship between GSK3 and contractility of glioblastoma cells.  
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